BPH Global Launches Lab Testing for Seaweed-Based Male Health Supplement
BPH Global advances men’s health supplement with Singapore testing agreement
BPH Global has executed a binding services agreement with Temasek Innovation Holdings Pte Ltd (TPIH), an operating entity of Temasek Polytechnic, Singapore, enabling commencement of a two-stage, cell-based efficacy testing programme for Project Giddy-Up. The seaweed-based formulation targets male vitality, anti-fatigue, stress recovery and sleep support, representing a differentiated approach within the men’s health nutraceutical sector.
The testing programme is scheduled to run through to October 2026 under a 6-month term with an option to extend by two months. The agreement fee totals SGD 29,000 (plus GST), with all Project IP owned by BPH Global.
This milestone moves the project from formulation completion to active validation, a tangible step toward commercialisation. The company aims to secure listing on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine.
When big ASX news breaks, our subscribers know first
What is PDE-5 inhibition and why does it matter for male health supplements?
Phosphodiesterase-5 (PDE-5) is an enzyme that affects blood flow by breaking down a chemical messenger called cGMP, which relaxes blood vessels. PDE-5 inhibitors block this enzyme, allowing blood vessels to stay relaxed and improving circulation. This is the same mechanism behind well-known prescription treatments for erectile dysfunction.
Demonstrating PDE-5 inhibition in a natural seaweed-based formulation could differentiate Project Giddy-Up in the nutraceutical market, where most products rely on traditional herbal extracts rather than marine-derived compounds.
If the formulation demonstrates biological activity on this validated pathway, it strengthens both the regulatory submission and commercial positioning by providing measurable evidence of efficacy rather than relying on historical use claims alone.
Testing programme targets three biological pathways
The programme involves in-vitro (cell-based) testing rather than human clinical trials, designed to evaluate the formulation’s biological activity across pathways associated with male vitality, circulation and hormonal support.
Three primary assays will be conducted:
- PDE-5 Inhibition Assay — evaluates ability to inhibit phosphodiesterase-5, linked to blood flow and erectile response
- Nitric Oxide (NO) and cGMP Pathway Analysis — measures intracellular signalling in corpus cavernosum smooth muscle cells, relevant to vascular relaxation
- Testosterone Production Assessment — evaluates effects on testosterone synthesis in Leydig cells, relevant to endocrine function
ICP-MS analysis will also assess heavy metals including arsenic, mercury and lead for product safety validation. Two candidate formulations will be compared, with the higher-performing formulation advancing to subsequent development stages.
Testing across multiple pathways provides a broader evidence base for regulatory submission, while safety testing supports TGA requirements for complementary medicines.
Agreement terms and deliverables
The services agreement establishes a structured framework for the testing programme with milestone-based payments and clear IP ownership.
| Term | Detail |
|---|---|
| Scope | Two-stage, cell-based efficacy testing plus safety analysis |
| Fees | SGD 29,000 (plus GST), milestone-based instalments |
| Timeline | 6 months with 2-month extension option |
| IP Ownership | All Project IP owned by BPH Global |
The agreement includes mutual confidentiality obligations covering all project information, with standard termination rights including breach provisions and 30-day notice requirements.
Final deliverables comprise a project report detailing methodology, results and interpretation of the testing programme.
The next major ASX story will hit our subscribers first
Regulatory pathway and next steps
The company confirms its regulatory strategy remains unchanged, with Project Giddy-Up targeting listing on the Australian Register of Therapeutic Goods (ARTG) as a TGA-listed complementary medicine (AUST L). Testing results will support the scientific evidence base, formulation optimisation and regulatory positioning.
Immediate next steps include:
- Commence laboratory testing activities with TPIH
- Progress evaluation of formulation efficacy and optimisation opportunities
- Advance development milestones aligned with regulatory strategy
The AUST L pathway represents a defined regulatory route in Australia for complementary medicines, with lower evidentiary requirements than prescription medicines while still requiring demonstration of safety and quality. Successful testing de-risks the submission process by providing cell-based efficacy data to support product claims.
Investment context
This agreement represents a validation milestone within a longer commercialisation journey for BPH Global (ASX: BP8). Seaweed-based formulations represent a relatively novel approach in men’s health nutraceuticals, which have traditionally relied on terrestrial plant extracts.
The testing programme is expected to conclude by October 2026, providing a defined near-term catalyst that investors can track against structured deliverables. Results from the three biological pathway assays will determine which formulation advances and inform the regulatory submission strategy.
While cell-based testing does not replace clinical trials in demonstrating human efficacy, it provides preliminary evidence of biological activity that supports both regulatory applications for complementary medicines and commercial differentiation claims in a competitive market.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get biotech developments, clinical trial updates and regulatory milestones delivered straight to your inbox the moment they hit the market.